PMID- 30591748
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 2090-911X (Electronic)
IS  - 1110-2608 (Print)
IS  - 1110-2608 (Linking)
VI  - 70
IP  - 4
DP  - 2018 Dec
TI  - XANTUS-EL: A real-world, prospective, observational study of patients treated 
      with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, 
      Middle East, Africa and Latin America.
PG  - 307-313
LID - 10.1016/j.ehj.2018.09.002 [doi]
AB  - BACKGROUND: The prospective, observational XANTUS study demonstrated low rates of 
      stroke and major bleeding in real-world rivaroxaban-treated patients with 
      non-valvular atrial fibrillation (NVAF) from Western Europe, Canada and Israel. 
      XANTUS-EL is a component of the overall XANTUS programme and enrolled patients 
      with NVAF treated with rivaroxaban from Eastern Europe, the Middle East and 
      Africa (EEMEA) and Latin America. METHODS: Patients with NVAF starting 
      rivaroxaban for stroke prevention were consecutively recruited and followed for 
      1 year, at approximately 3-month intervals, or for >/=30 days after permanent 
      rivaroxaban discontinuation. Primary outcomes were major bleeding, adverse events 
      (AEs), serious AEs and all-cause mortality. Secondary outcomes included stroke, 
      non-central nervous system systemic embolism (non-CNS SE), transient ischaemic 
      attack (TIA), myocardial infarction (MI) and non-major bleeding. All major 
      outcomes were centrally adjudicated. RESULTS: Overall, 2064 patients were 
      enrolled; mean age +/- standard deviation was 67.1 +/- 11.32 years; 49.3% were male. 
      Co-morbidities included heart failure (30.9%), hypertension (84.2%), diabetes 
      mellitus (26.5%), prior stroke/non-CNS SE/TIA (16.2%) and prior MI (10.7%). Mean 
      CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were 2.0, 3.6 and 1.6, 
      respectively. Treatment-emergent event rates were (events/100 patient-years, [95% 
      confidence interval]): major bleeding 0.9 (0.5-1.4); all-cause mortality 1.7 
      (1.2-2.4); stroke/non-CNS SE 0.7 (0.4-1.2); any AE 18.1 (16.2-20.1) and any 
      serious AE 8.3 (7.0-9.7). One-year treatment persistence was 81.9%. CONCLUSIONS: 
      XANTUS-EL confirmed low stroke and major bleeding rates in patients with NVAF 
      from EEMEA and Latin America. The population was younger but with more heart 
      failure and hypertension than XANTUS; stroke/SE rate was similar but major 
      bleeding lower.
FAU - Martinez, Carlos Arturo Arean
AU  - Martinez CAA
AD  - Department of Interventional Cardiology, General Hospital "Dr Miguel Silva", 
      Morelia, Michoacan, Mexico.
FAU - Lanas, Fernando
AU  - Lanas F
AD  - Departamento de Medicina Interna, Facultad de Medicina, Universidad de La 
      Frontera, Temuco, Chile.
FAU - Radaideh, Ghazi
AU  - Radaideh G
AD  - Department of Cardiology, Rashid Hospital, Dubai Health Authority, Dubai, United 
      Arab Emirates.
FAU - Kharabsheh, Suleiman M
AU  - Kharabsheh SM
AD  - Department of Cardiovascular Diseases, King Faisal Specialist Hospital and 
      Research Center, Riyadh, Saudi Arabia.
FAU - Lambelet, Marc
AU  - Lambelet M
AD  - Chrestos Concept GmbH & Co KG, Essen, Germany.
FAU - Viaud, Marco Antonio Lavagnino
AU  - Viaud MAL
AD  - Medical Affairs, Bayer AG, NJ, USA.
FAU - Ziadeh, Naser Samih
AU  - Ziadeh NS
AD  - Medical Affairs, Bayer AG, Amman, Jordan.
FAU - Turpie, Alexander G G
AU  - Turpie AGG
AD  - Department of Medicine, McMaster University, Hamilton, ON, Canada.
CN  - XANTUS Investigators
LA  - eng
PT  - Journal Article
DEP - 20180924
PL  - Germany
TA  - Egypt Heart J
JT  - The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of 
      Cardiology
JID - 9106952
PMC - PMC6303362
OTO - NOTNLM
OT  - AE, adverse event
OT  - AF, atrial fibrillation
OT  - CI, confidence interval
OT  - CNS, central nervous system
OT  - CrCl, creatinine clearance
OT  - EEMEA
OT  - EEMEA, Eastern Europe the Middle East and Africa
OT  - ISTH, International Society on Thrombosis and Haemostasis
OT  - Latin America
OT  - MI, myocardial infarction
OT  - NOAC, non-vitamin K antagonist oral anticoagulant
OT  - NVAF, non-valvular atrial fibrillation
OT  - PE, pulmonary embolism
OT  - Real-world
OT  - Rivaroxaban
OT  - SAE, serious adverse event
OT  - SD, standard deviation
OT  - SE, systemic embolism
OT  - Stroke prevention
OT  - TIA, transient ischaemic attack
OT  - VKA, vitamin K antagonist
OT  - od, once daily
EDAT- 2018/12/29 06:00
MHDA- 2018/12/29 06:01
PMCR- 2018/09/24
CRDT- 2018/12/29 06:00
PHST- 2018/03/19 00:00 [received]
PHST- 2018/09/02 00:00 [accepted]
PHST- 2018/12/29 06:00 [entrez]
PHST- 2018/12/29 06:00 [pubmed]
PHST- 2018/12/29 06:01 [medline]
PHST- 2018/09/24 00:00 [pmc-release]
AID - S1110-2608(18)30018-8 [pii]
AID - 10.1016/j.ehj.2018.09.002 [doi]
PST - ppublish
SO  - Egypt Heart J. 2018 Dec;70(4):307-313. doi: 10.1016/j.ehj.2018.09.002. Epub 2018 
      Sep 24.